188 related articles for article (PubMed ID: 37311439)
1. Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness.
Mannino M; Piccerillo A; Fabbrocini G; Quaglino P; Argenziano G; Dika E; Ascierto PA; Pellacani G; Longo C; Fargnoli MC; Bianchi L; Calzavara-Pinton P; Zalaudek I; Fava P; Scalvenzi M; Bocchino E; Di Stefani A; Peris K;
Dermatology; 2023; 239(6):868-876. PubMed ID: 37311439
[TBL] [Abstract][Full Text] [Related]
2. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
[TBL] [Abstract][Full Text] [Related]
4. Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.
Mesti T; Sever M; Ocvirk J
Dermatology; 2023; 239(1):158-164. PubMed ID: 35896082
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.
Lear JT; Migden MR; Lewis KD; Chang ALS; Guminski A; Gutzmer R; Dirix L; Combemale P; Stratigos A; Plummer R; Castro H; Yi T; Mone M; Zhou J; Trefzer U; Kaatz M; Loquai C; Kudchadkar R; Sellami D; Dummer R
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):372-381. PubMed ID: 28846163
[TBL] [Abstract][Full Text] [Related]
6. Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.
Kurnia Wijaya J; Djawad K; Wahab S; Nurdin A; Irawan Anwar A
Actas Dermosifiliogr; 2022 May; 113(5):443-450. PubMed ID: 35697404
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.
Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR
Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507
[TBL] [Abstract][Full Text] [Related]
8. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion.
Dummer R; Ascierto PA; Basset-Seguin N; Dréno B; Garbe C; Gutzmer R; Hauschild A; Krattinger R; Lear JT; Malvehy J; Schadendorf D; Grob JJ
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):1944-1956. PubMed ID: 31990414
[TBL] [Abstract][Full Text] [Related]
9. Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis.
Gutzmer R; Robert C; Loquai C; Schadendorf D; Squittieri N; Arntz R; Martelli S; Dummer R
BMC Cancer; 2021 Nov; 21(1):1244. PubMed ID: 34798846
[TBL] [Abstract][Full Text] [Related]
10. Real-World Experience of Vismodegib in Advanced Basal Cell Carcinoma at a Canadian Cancer Center.
Tong J; Mitchell B; Roth K; Logan D; Ernst S
J Cutan Med Surg; 2022; 26(2):143-148. PubMed ID: 34663118
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of Hedgehog pathway inhibitors used in the treatment of advanced or treatment-refractory basal cell carcinoma.
Lear JT; Morris LM; Ness DB; Lewis LD
Expert Rev Clin Pharmacol; 2023; 16(12):1211-1220. PubMed ID: 37975712
[TBL] [Abstract][Full Text] [Related]
12. Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study.
Moreno-Arrones OM; Béa-Ardebol S; Mayo-Martinez F; Pérez-Pastor G; Torres-Navarro I; Bonfill-Ortí M; Deza G; Ruiz-Salas V; Masferrer E; Feal C; Turrión-Merino L; Toll A; Yébenes M; Galiano-Mejías S; Jaka A; Ferrandiz-Pulido C; Florez A; Hernández-Hernández N; Fernández-de-Misa R; Rios-Buceta L; Sanmartin O
Actas Dermosifiliogr; 2023; 114(7):T565-T571. PubMed ID: 37302483
[TBL] [Abstract][Full Text] [Related]
13. Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study.
Moreno-Arrones OM; Béa-Ardebol S; Mayo-Martinez F; Pérez-Pastor G; Torres-Navarro I; Bonfill-Ortí M; Deza G; Ruiz-Salas V; Masferrer E; Feal C; Turrión-Merino L; Toll A; Yébenes M; Galiano-Mejías S; Jaka A; Ferrandiz-Pulido C; Florez A; Hernández-Hernández N; Fernández-de-Misa R; Rios-Buceta L; Sanmartin O
Actas Dermosifiliogr; 2023; 114(7):565-571. PubMed ID: 37088285
[TBL] [Abstract][Full Text] [Related]
14. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.
Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW
J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation.
Villani A; Scalvenzi M; Micali G; Lacarrubba F; Genco L; Ruggiero A; Fornaro L; Guerrasio G; Potestio L
Expert Opin Drug Saf; 2023; 22(7):525-531. PubMed ID: 37326221
[TBL] [Abstract][Full Text] [Related]
16. Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma.
Lear JT; Dummer R; Guminski A
Oncotarget; 2021 Dec; 12(26):2531-2540. PubMed ID: 34966484
[TBL] [Abstract][Full Text] [Related]
17. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
18. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
